These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline. Technol Eval Cent Assess Program Exec Summ; 2013 Feb; 27(5):1-4. PubMed ID: 23589929 [No Abstract] [Full Text] [Related]
9. Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making. Zannas AS; Doraiswamy PM; Shpanskaya KS; Murphy KR; Petrella JR; Burke JR; Wong TZ Neurocase; 2014 Aug; 20(4):466-73. PubMed ID: 23672654 [TBL] [Abstract][Full Text] [Related]
10. Florbetapir F 18 for brain imaging of β-amyloid plaques. Romano M; Buratti E Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322 [TBL] [Abstract][Full Text] [Related]
11. Amyloid imaging: liberal or conservative? Let the data decide. Jagust WJ Arch Neurol; 2011 Nov; 68(11):1377-8. PubMed ID: 21747005 [No Abstract] [Full Text] [Related]
12. Amyloid imaging in depression: a predictor of Alzheimer's disease? Camacho V; Lleó A Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):711-3. PubMed ID: 24604593 [No Abstract] [Full Text] [Related]
13. 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study. Park MA; Padera RF; Belanger A; Dubey S; Hwang DH; Veeranna V; Falk RH; Di Carli MF; Dorbala S Circ Cardiovasc Imaging; 2015 Aug; 8(8):. PubMed ID: 26259579 [TBL] [Abstract][Full Text] [Related]
14. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. Okamura N; Yanai K IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149 [TBL] [Abstract][Full Text] [Related]
16. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Grundman M; Pontecorvo MJ; Salloway SP; Doraiswamy PM; Fleisher AS; Sadowsky CH; Nair AK; Siderowf A; Lu M; Arora AK; Agbulos A; Flitter ML; Krautkramer MJ; Sarsour K; Skovronsky DM; Mintun MA; Alzheimer Dis Assoc Disord; 2013; 27(1):4-15. PubMed ID: 23203162 [TBL] [Abstract][Full Text] [Related]
17. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques. Wey SP; Weng CC; Lin KJ; Yao CH; Yen TC; Kung HF; Skovronsky D; Kung MP Nucl Med Biol; 2009 May; 36(4):411-7. PubMed ID: 19423009 [TBL] [Abstract][Full Text] [Related]
18. Radioactive agent approved as part of Alzheimer disease workup. Thompson CA Am J Health Syst Pharm; 2012 May; 69(10):818. PubMed ID: 22555074 [No Abstract] [Full Text] [Related]
19. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898 [TBL] [Abstract][Full Text] [Related]
20. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study. Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]